Bijal D. Shah, MD
The current state of treatment for patients with mantle cell lymphoma (MCL), continues to be challenging, according to Bijal D. Shah, MD.
, Shah discussed the challenge of treating this highly heterogeneous disease, how to choose the optimal treatment regimen, and the ongoing role of BTK inhibitors.
OncLive: How would you currently describe the state of MCL treatment?
MCL is a clinically and genomically heterogeneous disease. One of the reasons I first got excited about MCL is that it's a very rare lymphoma. I thought I could figure this out and contribute something major, because how much variability can there be in this one lymphoma that makes up 6% to 8% of B-cell lymphomas? I learned very quickly that there is quite a bit of variability, in fact. One of our first papers was a review paper titled, “Mantle cell lymphoma is a clinically heterogeneous disease.” That's the first thing I would want people to take home: there is no one-size-fits-all [approach].
... to read the full story